Document Detail


Efficacy of menatetrenone (vitamin K2) against non-vertebral and hip fractures in patients with neurological diseases: meta-analysis of three randomized, controlled trials.
MedLine Citation:
PMID:  19499964     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND AND OBJECTIVE: Patients with neurological diseases such as Alzheimer's disease, stroke and Parkinson's disease have been reported to have vitamin K deficiency secondary to malnutrition, which increases the risk of non-vertebral and hip fractures. The purpose of the present study was to clarify the efficacy of menatetrenone (vitamin K(2)) against non-vertebral and hip fractures in patients with neurological diseases. METHODS: A literature search was conducted on PubMed from January 1995 to July 2008 to identify randomized controlled trials (RCTs) of use of menatetrenone against non-vertebral and hip fractures in patients with neurological diseases. A meta-analysis of all RCTs meeting these criteria was then performed. RESULTS: Three RCTs of patients with Alzheimer's disease (n = 178, mean age 78 years), stroke (n = 99, mean age 66 years) and Parkinson's disease (n = 110, mean age 72 years) met the criteria for meta-analysis. These RCTs did not include placebo controls but did have non-treatment controls. According to the meta-analysis, the overall relative risks (95% confidence intervals) for non-vertebral and hip fractures with menatetrenone treatment compared with non-treatment were 0.13 (0.05, 0.35) and 0.14 (0.05, 0.43), respectively, in patients with neurological diseases. No severe adverse events were reported with menatetrenone treatment. CONCLUSION: The present meta-analysis of three RCTs suggests that there is efficacy for menatetrenone treatment against non-vertebral and hip fractures among patients with neurological diseases. Further larger placebo-controlled trials are needed to confirm the results of the present study.
Authors:
Jun Iwamoto; Hideo Matsumoto; Tsuyoshi Takeda
Related Documents :
16122024 - Late vertebral body fracture after lumbar transpedicular fixation. report of three cases.
8506884 - Association of osteoporotic vertebral compression fractures with impaired functional st...
15977464 - Vertebral fracture risk reduction with risedronate in post-menopausal women with osteop...
1110414 - Increased uptake of 99mtc-sulfur colloid in vertebral compression fractures.
9715444 - Mechanical evaluation of a new minimum-contact plate for internal fracture fixation.
824804 - Terminal plate fracture in vertebrae of the aged.
Publication Detail:
Type:  Journal Article; Meta-Analysis; Review    
Journal Detail:
Title:  Clinical drug investigation     Volume:  29     ISSN:  1173-2563     ISO Abbreviation:  Clin Drug Investig     Publication Date:  2009  
Date Detail:
Created Date:  2009-06-08     Completed Date:  2009-08-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9504817     Medline TA:  Clin Drug Investig     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  471-9     Citation Subset:  IM    
Affiliation:
Institute for Integrated Sports Medicine, Keio University School of Medicine, Tokyo, Japan. jiwamoto@sc.itc.keio.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Bone Density Conservation Agents / therapeutic use*
Brain Diseases / complications*
Female
Fractures, Bone / complications*,  drug therapy*
Hip Fractures / complications,  drug therapy
Humans
Male
Randomized Controlled Trials as Topic
Vitamin K 2 / analogs & derivatives*,  therapeutic use
Chemical
Reg. No./Substance:
0/Bone Density Conservation Agents; 11032-49-8/Vitamin K 2; 863-61-6/menatetrenone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effectiveness and tolerability of fixed-dose combination enalapril plus nitrendipine in hypertensive...
Next Document:  Management of metabolic cytochrome P450 3A4 drug-drug interaction between everolimus and azole antif...